Science and Health News

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.

Throughout the COVID-19 pandemic, there has been much uncertainty about how long immunity lasts after someone who is unvaccinated is infected with SARS-CoV-2.

Study is the first to demonstrate cross-protective immunity by vaccines

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites.

Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.

Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer.

The COVID-19 pandemic has highlighted the importance of preventive health behaviors. While public health experts agree that we won’t have an approved and widely available COVID-19 vaccine for some time, there are steps that people can take to stay healthy and safe. That includes getting the seasonal flu vaccine. So today we’re announcing new steps as part of our continued work to help support vaccine efforts.

With computer models and lab experiments, researchers are working on a strategy for vaccines that could protect against any influenza virus.